| Patents for C07K 5 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof (30,692) |
|---|
| 10/04/2001 | WO2001072956A2 Compounds and methods for modulating desmosomal cadherin-mediated functions |
| 10/04/2001 | WO2001072829A2 Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| 10/04/2001 | WO2001072770A1 Insulin potentiating peptides |
| 10/04/2001 | WO2001072701A1 Ceramide derivatives and method of use |
| 10/04/2001 | WO2001072324A1 Lactams as inhibitors of a-beta protein production |
| 10/04/2001 | WO2001000663A3 Catalytically active recombinant memapsin and methods of use thereof |
| 10/04/2001 | WO2000035941A3 Combinatorial process for preparing polyamines |
| 10/04/2001 | EP1144434A3 Combinatorial process for preparing polyamines |
| 10/04/2001 | EP1137763A1 Glucoamylases with n-terminal extensions |
| 10/04/2001 | EP1137662A1 Pharmaceutical compositions comprising quinapril magnesium |
| 10/04/2001 | EP1137661A1 Procollagen c-proteinase inhibitors |
| 10/04/2001 | EP0853614B1 Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors |
| 10/04/2001 | EP0815123B1 Beta-sheet mimetics and use thereof as protease inhibitors |
| 10/04/2001 | EP0802909B1 Substituted oxazolidine calpain and/or cathepsin b inhibitors |
| 10/04/2001 | EP0688314B1 Prodrug derivatives of enzyme inhibitors with hydroxyl groups, methods of preparing them and their use |
| 10/04/2001 | CA2404528A1 Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| 10/04/2001 | CA2404202A1 Compounds and methods for modulating desmosomal cadherin-mediated functions |
| 10/04/2001 | CA2402769A1 Ceramide derivatives and method of use |
| 10/04/2001 | CA2401120A1 Lactams as inhibitors of a-beta protein production |
| 10/03/2001 | CN1315965A Hepatitis C inhibitor peptides |
| 10/03/2001 | CN1315963A Benzodiazepines and benzothiazepines derivatives and HBSAG peptides binding to annexins, their compositions and use |
| 10/03/2001 | CN1315959A N-Alkylaspartyldipeptide ester derivatives and sweeteners |
| 10/03/2001 | CN1315958A Method for preparing crystal of aspartame derivative excellent in stability |
| 10/03/2001 | CN1315957A Process for preparation of neotame |
| 10/02/2001 | US6297380 Process and intermediates for growth hormone secretagogues |
| 10/02/2001 | US6297217 Boronic ester and acid compounds, synthesis and uses |
| 10/02/2001 | US6297216 Administering a dipeptide derivative to mammals |
| 10/02/2001 | US6296850 Apoptosis-related compounds and their use |
| 09/27/2001 | WO2001070746A1 Furoisoquinoline derivatives, process for producing the same and use thereof |
| 09/27/2001 | WO2001070672A2 Compounds and methods to treat alzheimer's disease |
| 09/27/2001 | WO2001070337A1 Spiropiperidine derivatives as melanocortin receptor agonists |
| 09/27/2001 | WO2001070275A2 Polyglutamic acid-camptothecin conjugates and methods of preparation |
| 09/27/2001 | WO2001070049A1 Stability enhancement of sweeteners using salts containing divalent or trivalent cations |
| 09/27/2001 | WO2001018232A3 Drug target isogenes: polymorphisms in the uncoupling protein 3 (mitochondrial, proton carrier) gene |
| 09/27/2001 | WO2001000665A3 Inhibitors of memapsin 2 and use thereof |
| 09/27/2001 | WO2000061541A3 Pharmaceutical compounds |
| 09/27/2001 | DE10012120A1 New ligand, comprising therapeutic or diagnostic agent bonded non-covalently with substance having high affinity to transport molecule |
| 09/27/2001 | CA2404226A1 Furoisoquinoline derivatives, process for producing the same and use thereof |
| 09/27/2001 | CA2403631A1 Spiropiperidine derivatives as melanocortin receptor agonists |
| 09/27/2001 | CA2402643A1 Polyglutamic acid-camptothecin conjugates and methods of preparation |
| 09/27/2001 | CA2401749A1 Compounds and methods to treat alzheimer's disease |
| 09/26/2001 | EP1136498A1 Inhibitors of serine proteases, particularly hepatitis c virus NS3 protease |
| 09/26/2001 | EP1135406A1 Gamma-ketoacid tetrapeptides as inhibitors of caspase-3 |
| 09/26/2001 | EP1135151A1 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 09/26/2001 | EP0802922B1 Novel amino acid derivatives, method of producing them and pharmaceutical compositions containing these compounds |
| 09/26/2001 | EP0762887B1 Acylated enol derivatives as prodrugs of elastase inhibitors |
| 09/26/2001 | EP0649426B1 Inhibitors of retroviral proteases |
| 09/26/2001 | CN1314912A Tartrate salt of a sabstituted dipentide as growth hormone secretagogue |
| 09/26/2001 | CN1314883A Amino acid derivatives and drug containing the same as the active ingredient |
| 09/26/2001 | CN1071751C Reversible protease inhibitors |
| 09/25/2001 | US6294686 Aspartame crystals and process for the preparation thereof |
| 09/25/2001 | US6294534 Treatment of disorders responsive to the activation of melanocortin receptors, such as obesity, diabetes or male or female sexual dysfunction. |
| 09/25/2001 | US6294525 Reverse-turn mimetics and methods relating thereto |
| 09/25/2001 | US6294062 Method and device for electrochemical immunoassay of multiple analytes |
| 09/25/2001 | CA1341296C 2-azabicycloalkane-3-carboxylic acid derivatives, processes for their preparation, agents containing these compounds and their use |
| 09/20/2001 | WO2001068678A2 Peptides that selectively bind to expanded polyglutamine repeat domains and methods of use thereof |
| 09/20/2001 | WO2001068655A2 Caprolactam derivatives and uses thereof |
| 09/20/2001 | WO2001068145A2 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
| 09/20/2001 | WO2001068142A1 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 09/20/2001 | WO2001068115A1 Process for producing peptide sequences possessing anti-hypertension activity |
| 09/20/2001 | WO2001068114A1 Novel peptides with anti-hypertensive activity |
| 09/20/2001 | WO2001068113A1 Anti-hypertensive peptides |
| 09/20/2001 | WO2001047949A9 Aspartame derivative crystals |
| 09/20/2001 | WO2001028579A3 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 09/20/2001 | WO2001010456A3 Peptides that block viral infectivity and methods of use thereof |
| 09/20/2001 | WO2000009537A3 Compounds having growth hormone releasing activity |
| 09/20/2001 | US20010023301 By hydrogenating a mixture of 3,3-dimethylbutyraldehyde and N-benzyloxycarbonyl-L-alpha-aspartyl-L-phenylalanine-1-methyl ester in methanolic solvent, separating catalyst, desolventizing, adding water, separating solid neotame |
| 09/20/2001 | US20010023244 Thrombin inhibitors |
| 09/20/2001 | CA2401873A1 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
| 09/19/2001 | EP1133518A1 A METHOD FOR THE PREPARATION OF N-NEOHEXYL-$g(a)-ASPARTYL-L-PHENYLALANINE METHYL ESTER FROM IMIDAZOLIDIN-4-ONE INTERMEDIATES |
| 09/19/2001 | EP0889901B1 Process and intermediates for the synthesis of lhrh antagonists |
| 09/19/2001 | EP0802986B1 Methods of determining endogenous thrombin potential (etp) and thrombin substrates for use in said methods |
| 09/19/2001 | EP0700302B1 Device for treating diabetes mellitus |
| 09/19/2001 | EP0640099B1 Peptides having tachykinin antagonist activity |
| 09/19/2001 | EP0600062B1 Polymer-bound paclitaxel derivatives |
| 09/19/2001 | CN1313863A Inhibitors of urokinase and blood vessel fomation |
| 09/19/2001 | CN1313855A Inhibitors of alpha4Betal mediated cell adhesion alpha Beta |
| 09/19/2001 | CN1313846A C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cystenine proteases |
| 09/18/2001 | US6291640 Peptidomimetic inhibitors of the human cytomegalovirus protease |
| 09/18/2001 | US6291511 Biarylalkanoic acids as cell adhesion inhibitors |
| 09/18/2001 | US6291452 Cholecystokinin antagonists. |
| 09/18/2001 | US6291432 (r)-n-(2-methylbenzyl)-3-((2s, 3s)-3-(n-(2-chromonecarbonyl)-l-asparaginyl)amino-2-hydroxy-4-phenylbutano yl)-5,5-dimethyl-1,3-thiazolidine-4-carboxamide can be given as a typical example of this compound. |
| 09/18/2001 | US6291004 Dipeptide sweeteners |
| 09/13/2001 | WO2001066791A1 Method of screening inducible nitric oxide synthase activation inhibitor |
| 09/13/2001 | WO2001066564A2 Gamma-secretase inhibitors |
| 09/13/2001 | WO2001066147A2 Antimicrobial compounds and formulations |
| 09/13/2001 | WO2001009169A3 Cysteine protease inhibitors |
| 09/13/2001 | US20010021718 Antiscarring agent |
| 09/13/2001 | US20010021713 Thromboresistant materials incorporating pyrazinone protease inhibitors |
| 09/13/2001 | US20010021388 Cyclization of a triether with a diamine compound |
| 09/13/2001 | CA2401525A1 Gamma-secretase inhibitors |
| 09/13/2001 | CA2400410A1 Antimicrobial compounds and formulations |
| 09/12/2001 | EP1132471A2 TNF-binding proteins |
| 09/12/2001 | EP1132396A1 Physiologically active peptides |
| 09/12/2001 | EP1132395A2 Process for the preparation of a pharmacologically active peptide |
| 09/12/2001 | EP1132388A2 Hexahydropyrazolo[4,3-c]pyridine metabolites |
| 09/12/2001 | EP1131636A1 Antibodies to peptides that target git receptors and related methods |
| 09/12/2001 | EP1131634A2 Determining the mechanism of beta-amyloid peptide generation |
| 09/12/2001 | EP1131351A2 Peptides that modulate the interaction of b class ephrins and pdz domains |
| 09/12/2001 | EP1131341A1 Compound for inhibiting the influx of polymorphonuclear leukocytes (pmns) in a tissue, it's selection, pharmaceuticial compositions and use |